Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2329-2338

  Hu, Yongzhen ^a   Kirito, Keita ^a   Yoshida, Kozue ^a   Mitsumori, Toru ^a   Nakajima, Kei ^a   Nozaki, Yumi ^a   Hamanaka, Satoshi ^a   Nagashima, Takahiro ^a   Kunitama, Masae ^a   Sakoe, Kumi ^a   Komatsu, Norio ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; DEXAMETHASONE; ECHINOMYCIN; HYPOXIA INDUCIBLE FACTOR 1; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; SURVIVIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; ECHINOMYCIN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INSULIN-LIKE GROWTH FACTOR I; MELPHALAN; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; RNA, SMALL INTERFERING;

EID: 68849096240     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0150     Document Type: Article

References (44)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology ofmultiple myeloma: clinical applications. Blood 2004;104:607-18.
2. Semenza GL. Life with oxygen. Science 2007;318:62-4.
3. Rankin EB, Giaccia AJ. The role ofhypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15:678-85.
4. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
5. Pollard PJ, Spencer-Dene B, Shukla D, et al. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 2007;11:311-9.
6. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 2005;7:77-85.
7. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
8. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-9.
9. Kirito K, Fox N, Komatsu N, Kaushansky K. Thrombopoietin enhances expression ofvascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1α. Blood 2005;105:4258-63.
10. Jung JE, Lee HG, Cho IH, et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005;19:1296-8.
11. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60.
12. Belaiba RS, Bonello S, Zahringer C, et al. Hypoxia up-regulates HIF-1α transcription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007;18:4691-7.
13. Rius J, Guma M, Schachtrup C, et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1aα. Nature 2008;453:807-11.
14. van Uden P, Kenneth NS, Rocha S. Regulation ofh ypoxia-inducible factor-1α by NF-κB. Biochem J 2008;412:477-84.
15. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 2008;105:2622-7.
16. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008;111:3131-6.
17. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity ofheat shock protein-90 inhibition. Blood 2006;107:1092-100.
18. Kirito K, Uchida M, Yamada M, Miura Y, Komatsu N. A distinct function of STAT proteins in erythropoietin signal transduction. J Biol Chem 1997;272:16507-13.
19. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004;64:1765-72.
20. Ogura M, Shibata T, Yi J, et al. A tumor-specific gene therapy strategy targeting dysregulation ofthe VHL/HIF pathway in renal cell carcinomas. Cancer Sci 2005;96:288-94.
21. Fang Y, Sullivan R, Graham CH. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 2007;313:867-77.
22. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-11.
23. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target ofrapa mycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
24. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856-61.
25. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002;99:4138-46.
26. Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 2006;12:4747-54.
27. Liu F, Wang P, Jiang X, et al. Antisense hypoxia-inducible factor 1α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008;99:2055-61.
28. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83.
29. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SC H66336 (lonafarnib) through Akt/mammalian target ofrap amycin-mediated increases in survivin expression. Clin Cancer Res 2008;14:1581-9.
30. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997;97:429-40.
31. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition ofthe insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.
32. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor ofhy poxia-inducible factor-1 DNA-binding activity. Cancer Res 2005;65:9047-55.
33. Vlaminck B, Toffoli S, Ghislain B, Demazy C, Raes M, Michiels C. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. Febs J 2007;274:5533-42.
34. Peng X-H, Karna P, Cao Z, Jiang B-H, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1{α} signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006;281:25903-14.
35. Asosingh K, De Raeve H, de Ridder M, et al. Role ofthe hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005;90:810-7.
36. Colla S, Tagliaferri S, Morandi F, et al. The new tumor-suppressor gene inhibitor ofgrowth family member 4 (ING4) regulates the production ofp roangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesis. Blood 2007;110:4464-75.
37. Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002;100:3925-9.
38. Cairns RA, Papandreou I, Sutphin PD, Denko NC. Metabolic targeting ofhypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A 2007;104:9445-50.
39. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
40. Birle DC, Hedley DW. Suppression ofthe hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007;67:1735-43.
41. Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity ofhypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1α C-terminal activation domain. Mol Cell Biol 2006;26:5895-907.
42. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J Biol Chem 2002;277:29936-44.
43. Chatterjee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression ofheat shock proteins 90{α} and {β} in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007;109:720-8.
44. Romagnoli M, Trichet V, David C, et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007;21:1070-8.